Clinic Roundup

• If it can raise enough capital in the near term, Omni Bio Pharmaceutical Inc., of Denver, said it plans to begin two new clinical trials to test the efficacy of alpha-1 antitrypsin as a treatment for Type I diabetes and graft-vs.-host disease (GVHD).